Literature DB >> 17470962

Zuclopenthixol in adults with intellectual disabilities and aggressive behaviours: discontinuation study.

Frank Haessler1, Thomas Glaser, Manfred Beneke, Akos F Pap, Ralf Bodenschatz, Olaf Reis.   

Abstract

We investigated the effects of zuclopenthixol on aggressive behaviour in patients with intellectual disabilities by randomly withdrawing it after a 6-week period of open treatment. Of the 49 patients responding to the treatment, 39 took part in a randomised withdrawal trial. The placebo subgroup (n=20) showed more aggressive behaviour as indicated by outcomes observed by external raters on the Modified Overt Aggression Scale than did the continuing subgroup (n=19). The results indicate that discontinuation of zuclopenthixolin this population leads to an increase in aggressive behaviour.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17470962     DOI: 10.1192/bjp.bp.105.016535

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  4 in total

Review 1.  Polypharmacy in the treatment of subjects with intellectual disability.

Authors:  Frank Häβler; Johannes Thome; Olaf Reis
Journal:  J Neural Transm (Vienna)       Date:  2014-05-25       Impact factor: 3.575

2.  Effectiveness of long-acting antipsychotics in clinical practice : 1. A retrospective, 18-month follow up and comparison between paliperidone palmitate, risperidone long-acting injection and zuclopenthixol decanoate.

Authors:  Matthew Cordiner; Polash Shajahan; Sarah McAvoy; Muhammad Bashir; Mark Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2016-02

Review 3.  Aggressive behaviour in adults with intellectual disability: defining the role of drug treatment.

Authors:  Patricia Oliver-Africano; Declan Murphy; Peter Tyrer
Journal:  CNS Drugs       Date:  2009-11       Impact factor: 5.749

4.  Management of psychotropic medications in adults with intellectual disability: a scoping review.

Authors:  Ashley Costello; Eithne Hudson; Susan Morrissey; Drona Sharma; Dervla Kelly; Owen Doody
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.